دورية أكاديمية
Therapeutic hotline. Treatment of androgenic alopecia with finasteride may result in a high grade prostate cancer in patients: fact or fiction?
| العنوان: | Therapeutic hotline. Treatment of androgenic alopecia with finasteride may result in a high grade prostate cancer in patients: fact or fiction? |
|---|---|
| المؤلفون: | Lynn R; Department of Dermatology, University of Illinois-Chicago, 808 S.Wood Street, Chicago, IL 60612-7300, USA. slickrikk808@hotmail.com, Krunic A |
| المصدر: | Dermatologic therapy [Dermatol Ther] 2010 Sep-Oct; Vol. 23 (5), pp. 544-6. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 9700070 Publication Model: Print Cited Medium: Internet ISSN: 1529-8019 (Electronic) Linking ISSN: 13960296 NLM ISO Abbreviation: Dermatol Ther Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: July/Aug. 2008- : Hoboken, NJ : Wiley-Blackwell Original Publication: Copenhagen : Munksgaard, c1996- |
| مواضيع طبية MeSH: | 5-alpha Reductase Inhibitors/*adverse effects , Alopecia/*drug therapy , Finasteride/*adverse effects , Prostatic Neoplasms/*epidemiology, 5-alpha Reductase Inhibitors/therapeutic use ; Finasteride/therapeutic use ; Humans ; Male ; Prostatic Hyperplasia/drug therapy ; Prostatic Neoplasms/chemically induced ; Prostatic Neoplasms/pathology ; Risk |
| مستخلص: | Finasteride at a dose of 1 mg (Propecia®) has been used for the treatment of androgenic alopecia in men. Though finasteride has been successfully used, there is ongoing controversy surrounding its use since the publication of the Prostate Cancer Prevention Trial (PCPT) which includes claims of increased risk for higher grade prostate cancers. This has produced confusion on consulting and treatment of patients interested in starting finasteride for androgenic alopecia. We felt there was a need to clarify further the results of PCPT for our readers and help understanding the real risk of prostate cancer development of patients on finasteride. In conclusion, we suggest the guidelines for treatment monitoring for patients on finasteride which based on comprehensive review of the trial presents safe treatment for androgenetic alopecia without the concern for the induction of high-grade prostate cancer. (© 2010 Wiley Periodicals, Inc.) |
| المشرفين على المادة: | 0 (5-alpha Reductase Inhibitors) 57GNO57U7G (Finasteride) |
| تواريخ الأحداث: | Date Created: 20100928 Date Completed: 20110302 Latest Revision: 20220309 |
| رمز التحديث: | 20221213 |
| DOI: | 10.1111/j.1529-8019.2010.01358.x |
| PMID: | 20868409 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1529-8019 |
|---|---|
| DOI: | 10.1111/j.1529-8019.2010.01358.x |